Edgar Filing: Leamon Christopher P - Form 4

Leamon Chris	stopher P									
Form 4										
October 06, 2	017									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									OMB APPROVAL	
	UNITED		CURITIES A Washington,			NGE (COMMISSION	OMB Number:	3235-0287	
subject to				GES IN BENEFICIAL OWNERSHI SECURITIES				Expires:January 3 200Estimated averageburden hours per response0		
Form 5 obligations may contin <i>See</i> Instruct 1(b).	Section 17(a	a) of the Publ		ding Com	pany	Act of	ge Act of 1934, f 1935 or Sectio 40	n		
(Print or Type Ro	esponses)									
1. Name and Ad Leamon Chri	ldress of Reporting l stopher P	Sym	2. Issuer Name and Ticker or Trading Symbol ENDOCYTE INC [ECYT]				 Relationship of Reporting Person(s) to Issuer (Check all applicable) 			
(Last)	(First) (M	(iddle) 3. D	3. Date of Earliest Transaction					.k an appliedok	-)	
3000 KENT .	AVE, SUITE A		(Month/Day/Year) 10/04/2017				Director 10% Owner X Officer (give title Other (specify below) below) Vice President of Research			
				nendment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
WEST LAFA	YETTE, IN 479	906					Form filed by M Person	More than One Re	eporting	
(City)	(State)	(Zip)	Table I - Non-I	Derivative S	ecurit	ties Acc	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Dat any (Month/Day/Y	Code	ion(A) or Dis (D) (Instr. 3, 4	sposed	l of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	10/04/2017		А	40,000 (1)	А	\$0	124,401 (2)	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Leamon Christopher P - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Leamon Christopher P 3000 KENT AVE, SUITE A1-100 WEST LAFAYETTE, IN 47906			Vice President of Research				

Signatures

/s/ Michael A. Sherman, Attorney-in-Fact for Christopher P. Leamon (power of attorney previously filed)

<u>**</u>Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted stock units that will vest and be paid 1/2 annually over a period of 2 years beginning on October 4, 2018, in the form of one share of common stock for each restricted stock unit.
- (2) Includes 2500 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

10/06/2017

Date